Advertisement

CCL21

  • Sherven Sharma
  • Minu K. Srivastava
  • Marni-Harris White
  • Dorthe Schaue
  • Maie St John
  • Gang Zhang
  • Percy Lee
  • Jay M. Lee
  • Steven Dubinett
Reference work entry

Abstract

Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.

Keywords

Chemokine CCL21 T lymphocytes Dendritic cells Immune activation Anti-tumor immune activity Lung cancer 

References

  1. Ashour AE, Turnquist HR, Singh RK, Talmadge JE, Solheim JC. CCL21-induced immune cell infiltration. Int Immunopharmacol. 2007;7(2):272–6. Epub 2006 Nov 13.CrossRefPubMedGoogle Scholar
  2. Baratelli F, et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med. 2008;6(1):38.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Coppola D, Mule JJ. Ectopic lymph nodes within human solid tumors. J Clin Oncol. 2008;26(27):4369–70.CrossRefPubMedGoogle Scholar
  4. Cyster J. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286:2098–102.CrossRefPubMedGoogle Scholar
  5. Dieu-Nosjean MC, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410–7.CrossRefPubMedGoogle Scholar
  6. Flanagan K, et al. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol. 2004;231(1–2):75–84. Epub 2005 Jan 21.CrossRefPubMedGoogle Scholar
  7. Friedman RS, et al. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol. 2006;7(10):1101–8. Epub 2006 Sep 10.CrossRefPubMedGoogle Scholar
  8. Gollmer K, et al. CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood. 2009;114(3):580–8. Epub 2009 May 18.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Kirk C, et al. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001a;61(24):8794–802.PubMedGoogle Scholar
  10. Kirk CJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001b;61(5):2062–70.PubMedGoogle Scholar
  11. Lapteva N, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009;17(9):1626–36. Epub 2009 Jun 16.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Liang CM, et al. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol. 2007;81(17):9502–11. Epub 2007 Jun 13.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Miller PW, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther. 2000;11(1):53–65.CrossRefPubMedGoogle Scholar
  14. Novak L, et al. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther. 2007;6(6):1755–64.CrossRefPubMedGoogle Scholar
  15. Sharma S, et al. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with Interleukin 7/Herpes Simplex Thymidine Kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther. 1997;4:1361–70.CrossRefPubMedGoogle Scholar
  16. Sharma S, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000;164(9):4558–63.CrossRefPubMedGoogle Scholar
  17. Tatsumi T, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003;63(19):6378–86.PubMedGoogle Scholar
  18. Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncol. 2007;30(3):631–9.PubMedGoogle Scholar
  19. Vicari AP, et al. Antitumor effects of the Mouse Chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165:1992–2000.CrossRefPubMedGoogle Scholar
  20. Yang SC, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res. 2004;10(8):2891–901.CrossRefPubMedGoogle Scholar
  21. Yang SC, et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006;66(6):3205–13.CrossRefPubMedGoogle Scholar
  22. Yousefieh N, et al. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2009;6:6.Google Scholar
  23. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology. 1993;25(4):338–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, New York (outside the USA) 2017

Authors and Affiliations

  • Sherven Sharma
    • 1
  • Minu K. Srivastava
    • 2
  • Marni-Harris White
    • 1
  • Dorthe Schaue
    • 2
  • Maie St John
    • 2
  • Gang Zhang
    • 2
  • Percy Lee
    • 2
  • Jay M. Lee
    • 2
  • Steven Dubinett
    • 1
  1. 1.Molecular Medicine Laboratory, VAGLAHSJCCC Lung Cancer Program, David Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.JCCC Lung Cancer Program, David Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations